On April 1, 2025, under the organization and coordination of the Shenzhen Municipal Communist Youth League and the Shenzhen Young Scientists Association, a cooperation negotiation meeting was held between two vice-presidential units of the Young Scientists Association—Shenzhen Cell Valley and Shenzhen Qianhai Taikang Hospital. Both sides conducted in-depth discussions on the cooperation of stem cell and exosome technology in the field of health management. This cooperation aims to integrate high-quality medical resources with cutting-edge biotechnology to provide innovative anti-aging and health management services for high-net-worth individuals, jointly promoting the innovation and development of the medical industry in the Greater Bay Area.

At the beginning of the meeting, Zhang Yuxiao, Director of the Advanced Medical Center at Shenzhen Qianhai Taikang Hospital, introduced in detail the hospital's development positioning and the featured services of its International Medical Department. Relying on the hospital's significant advantages in tumor treatment and anti-aging, the hospital is committed to building a high-end health management platform and looks forward to introducing cell therapy technology to provide more cutting-edge health management solutions for high-net-worth clients.

Li Xianxin, Vice President of Shenzhen Qianhai Taikang Hospital, emphasized that as an important layout of Taikang Medical in South China, the hospital always adheres to technology innovation to drive the upgrading of medical services, striving to build an innovative ecosystem of "Insurance + Medical Care + Health Management." The International Medical Department will focus on the health management needs of the sub-healthy population, relying on Taikang Insurance's vast customer resources to provide high-quality health management solutions for high-net-worth clients. He pointed out, "Safety and compliance are our primary principles. This cooperation will promote the hospital's introduction of the technological advantages of cell therapy in tumor treatment and anti-aging."

Shi Yuanyuan, Chairman of Shenzhen Cell Valley, introduced in detail the company's technological advantages and quality control systems in the fields of stem cells, NK cells, and exosomes. He stated that Shenzhen Cell Valley will fully leverage its R&D advantages to jointly explore the compliant application path of cell therapy technology in the field of health management with Shenzhen Qianhai Taikang Hospital, providing consumers with safe and effective health management services. At the same time, a complete service record system will be established to ensure traceability and prevent potential legal and public opinion risks. Shi Yuanyuan suggested that reference could be made to the policy experience of the Boao Lecheng International Medical Tourism Pilot Zone to explore compliant paths for stem cell clinical research. Furthermore, through the group's international business and medical service headquarters—Deep Harbour Cell Valley Healthcare and Technology Co.Ltd located in Qianhai—the company will cooperate with Shenzhen Qianhai Taikang Hospital and other hospitals to actively strive for policy support in the field of cell therapy in the Qianhai Free Trade Zone, promoting the innovative development of the cell therapy industry in the Greater Bay Area.

Also attending this meeting were Li Xiaoxia, Secondary Researcher of the United Front Work and Liaison Department of the Shenzhen Municipal Communist Youth League; Yu Yuanzhi, Secretary-General of the Shenzhen Young Scientists Association; Lü Zhuoyuan, General Manager of the Marketing Planning Department and Head of Marketing at Shenzhen Qianhai Taikang Hospital; Zhu Da, Director of the Medical Management Department Office at the Health Service Center; Li Chengliang, Associate Chief Physician of General Practice at the Advanced Medical Center; Xuan Fanxin, Head Nurse of the Advanced Medical Center; Chen Xinyi, Secretary to the Director of the Advanced Medical Center; Tang Xiaomeng, General Manager of Deep Harbour Cell Valley and Deputy General Manager of Shenzhen Cell Valley; Tang Hui, Business Director of Deep Harbour Cell Valley; and Wei Zheng, Head of the Administration Department of Shenzhen Cell Valley.

About Shenzhen Qianhai Taikang Hospital

Shenzhen Qianhai Taikang Hospital is a medical center integrating medicine, teaching, and research, constructed by the Fortune Global 500 company Taikang Insurance Group according to Grade II-A general hospital standards. Located in the core hub of the Guangdong-Hong Kong-Macao Greater Bay Area—the Qianhai Qianwan area of Shenzhen—the hospital has a planned investment of nearly 5 billion RMB, covers an area of 38,000 square meters, has a total construction area of 220,000 square meters, and plans for 1,100 beds. Construction commenced on November 30, 2020, and on July 19, 2024, it was approved for a Grade I general hospital medical practice license. It serves as Taikang's medical flagship in the Greater Bay Area. The hospital is configured with 45 disciplines according to Grade III-A general hospital standards, providing comprehensive outpatient and inpatient diagnosis and treatment services. The first batch of key medical centers under construction includes Digestive Diseases, Orthopedics and Sports Medicine, Urology and Andrology, and Oncology.